PCVX - Vaxcyte, Inc.
IEX Last Trade
85.83
-30.690 -35.757%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$116.52
-30.69
-26.34%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.72%
1 Month
-6.31%
3 Months
-24.28%
6 Months
15.32%
1 Year
40.72%
2 Year
84.08%
Key data
Stock price
$85.83
DAY RANGE
$85.79 - $116.52
52 WEEK RANGE
$60.09 - $121.06
52 WEEK CHANGE
$35.48
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Grant E. Pickering
Region: US
Website: vaxcyte.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vaxcyte.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.
Recent news